Esperion to Participate in Upcoming September Investor Conferences
The original release is unavailable here.
Esperion Therapeutics, Inc. on 6ix
Story so far
Earlier from Esperion Therapeutics
- HLS Therapeutics Announces Q2 2025 Financial Results
- Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update
- Esperion to Report Second Quarter 2025 Financial Results on August 5
- Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
- Esperion Appoints Craig Thompson to Board of Directors
Later from Esperion Therapeutics
- Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
- Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
- Oritain Extends Cutting-Edge Origin Verification to Leather for EUDR Readiness
- Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040
- Esperion Announces Proposed Public Offering of Common Stock
Follow Esperion Therapeutics into a list and get an email when it puts out news.
Follow Esperion Therapeutics